CD44 and cancer: Gonzalez et al. (2012) characterizes the CD44- CD44ICD pathway and its downstream genes, defining its critical role in various glycolytic pathways and cancer stem cell knockdown of CD44 by RNA interference or y-secretase inhibitors (GSIs) blocked proliferation, which was restored by CD44ICD overexpression.